Key Highlights
•
A new study on lecanemab, an Alzheimer’s drug, reveals that its target—small clumps of amyloid beta protein in the brain—is actually very similar to that of other anti-amyloid antibodies, challenging the idea that its lower rate of brain swelling side effects is due to a unique target.
Source →
•
Scientists demonstrated a new way to boost cancer immunotherapy by engineering CAR T-cells to express a glucose transporter called GLUT3, which helps them survive and fight tumors more effectively in preclinical models of glioblastoma, a deadly brain cancer.
Source →
•
Researchers have developed new, safer versions of iboga alkaloids, a plant-based compound known for pain relief and anxiety reduction, achieving these effects without harmful side effects and with added neuroprotective benefits.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
